Day: June 11, 2021

Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress — Ongoing ADVANCE II study evaluating DCP-001 in AML patients is nearing target enrollment of 20 patients —  Immunicum AB (publ; IMMU.ST) today presents clinical data showing DCP-001’s ability to induce immune responses to a broad range of tumor associated antigens in acute myeloid leukemia (AML) patients, as well as preclinical results of enhanced efficacy when combining DCP-001 with established AML treatment regimens, at the EHA 2021 Virtual Congress, held from June 9-17, 2021. The abstracts covering these presentations have been communicated previously. The E-posters can now be accessed through the conference platform and at the Company’s corporate website. “The data presented at the EHA conference underscores...

        New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with cold agglutinin disease, a serious and chronic autoimmune hemolytic anemia        Phase 3 data from the CADENZA study met the primary composite endpoint with statistical significance; secondary endpoint data were clinically meaningful Findings provide further evidence that sutimlimab results in rapid inhibition of C1-activated hemolysis within one week of treatment and had a sustained treatment effect throughout the studyPARIS – June 11, 2021 – Results from Part A of CADENZA, a pivotal Phase 3 double-blind, placebo-controlled study evaluating the safety and efficacy of sutimlimab in people with cold agglutinin disease (CAD) without a recent history...

– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 – – Agios to Host Investor Webcast Today at 7:30 a.m. ET – CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today reported a full analysis of updated data, including patient-reported outcome (PRO) measures, from its global Phase 3 ACTIVATE and ACTIVATE-T studies of mitapivat in adults with pyruvate kinase (PK) deficiency. Data from the studies will be featured in oral presentations on Tuesday, June 15, at the European Hematology Association (EHA) Virtual Congress. Consistent with previously announced topline data, the ACTIVATE and ACTIVATE-T...

First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal nocturnal hemoglobinuria (PNH) patients1New results are promising for potential use of iptacopan as monotherapy in PNH, a rare and life-threatening blood disorder2,3; results from a previous Phase II study showed iptacopan substantially improved hematological response as add-on to standard-of-care (eculizumab)4The FDA has granted Breakthrough Therapy Designation to iptacopan for PNH5; it also has received orphan drug designation for PNH from both the FDA and EMA6Iptacopan is also in development for several rare renal conditions with complement system (part of the innate immune system) involvement, targeting a key driver of these diseases7,8Recently...

Treatment with CYAD-211 generally well-tolerated at first two dose levels, with no evidence of Graft-versus-Host Disease observed Two partial responses observed among five evaluable patients Cell engraftment of CYAD-211 observed in all patients from dose level 2, with evidence of CAR T cells in all patients enrolled in first two dose cohorts Additional clinical data from the dose escalation trial are expected during second half 2021 Management to host conference call later today, June 11, at 2 p.m. CET / 8 a.m. ETMONT-SAINT-GUIBERT, Belgium, June 11, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced preliminary data from the Phase 1 IMMUNICY-1...

Press release 11 June 2021, 08:35 Trading in Sdiptech’s shares commences today on Nasdaq Stockholm Sdiptech AB (publ) announces that trading in the company’s ordinary shares of series B and preference shares (the “Shares”) will today begin on Nasdaq Stockholm’s main market. “Since the IPO in 2017, Sdiptech has almost doubled the number of employees, been properly established outside the Nordic region and had an average annual profit growth of 36 percent. I’m extra pleased about the fact that we are now classified as a Large Cap company, which is another proof of the great growth journey that Sdiptech has had in recent years. The shift to Nasdaq Stockholm is a hallmark of quality, a milestone on the road and another building block in our strategy for continued international growth”, says Jakob Holm, CEO of Sdiptech. The Shares...

The shareholders, the holders of subscription rights, the holders of debentures1, and the holders of convertible debentures are requested to attend the Extraordinary General Meeting of Shareholders to be held on Thursday 15 July 2021 at 11:30 a.m. at the offices of the Company, Bekaertstraat 2, 8550 Zwevegem (Belgium).AttachmentEGM1 Notice

Oslo, 11 June 2021 – Interoil Exploration and Production ASA (Interoil) regrets to inform about further delays in the preparation of the company’s annual report for 2020. The annual general meeting, and the report for the first quarter 2021 will also be postponed. The new dates are as follows. Annual Report 2020 – 25 June 2021Q1 Interim Financial Report – 16 July 2021Annual General Meeting – 28 July 2021 *************************** Interoil Exploration and Production ASA is a Norwegian based exploration and production company – listed on the Oslo Stock Exchange – with focus on Latin America. The Company is operator and license holder of several production and exploration assets in Colombia and Argentina. Interoil currently employs approximately 50 people and is headquartered in Oslo. This information is subject to the disclosure...

INVESTOR NEWS NO. 22/2021   DFDS reports monthly ferry volumes for freight and passengers to provide additional insight into the development of volume trends in DFDS’ European route network.DFDS ferry volumes              May   LTM*Freight 2020 2021 Change   2019-20 2020-21 ChangeLane metres, ‘000 2,782 3,650 31.2%   39,540 43,125 9.1%               Passenger 2020 2021 Change   2019-20 2020-21 ChangePassengers, ‘000 48 35 -27.3%   4,122 989 -76.0%*Last twelve months              Ferry – freight: Total volumes in May 2021 were 31.2% above 2020. Net adjustments for structural route changes reduced growth 3.2 ppt to 28.0%. The extraordinary volume growth in May 2021 vs 2020 reflected a recovery from the significant volume reductions in May 2020 caused by Covid-19 related lockdowns. Volumes in...

If you have an idea for a new product or service, but implementing a business project requires funds: temporary, monetary, or expert, you need a Fuji investor. Humanity has long thought about how to help startups with the search for investors. One of these ways, made possible by the development of the Internet – is crowdfunding. To get investments or coins, you need to register your project on a Fuji crowdfunding platform. As a rule, you will get many investors and the main return for them will be rather not material benefits, but the very idea of ​​participating in creating a new project. Of course, investors can offer you their investments in exchange for a share in your business, or further material rewards after your business generates income. This is the fundamental difference between crowdfunding and other types of financing. The...